Informação sobre produto
- 1,1-Dioxo-6-(trifluoromethyl)-1,2,3,4-tetrahydro-1λ6,2,4-benzothiadiazine-7-sulfonamide
- 1,1-Dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide
- 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide
- 3,4-Dihydro-6-(trifluoromethyl)-2H-1,2,4-
- 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
- 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiazide-7-sulfonamide 1,1-dioxide
- 3,4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1,1-dioxide
- 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
- 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-1,2,4-benzothiadiazine 1,1-dioxide
- 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
- Ver mais sinónimos
- 6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
- 6-Trifluoromethyl-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide
- 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
- Benzothiodiazine(2H-1,2,4)-7-Sulfonamide, 3,4-Dihydro-6-Trifluoromethyl)-1,1-Dioxide
- Bristab
- Bristurin
- Di-Ademil
- Dihydroflumethiazide
- Diucardin
- Diumide K
- Diuredemina
- Diurometon
- Elodrine
- Finuret
- Flutizide
- Glomerulin
- Hidroalogen
- Hidroflumetiazid
- Hidroflumetiazida
- Hydol
- Hydrenox
- Hydroflumethiazid
- Leodrine
- Metflorylthiazidine
- Methforylthiazidine
- NaClex
- NaClex (Glaxo)
- Nsc 44627
- Olmagran
- Rodiuran
- Rontyl
- Saluron
- Salutensin
- Sisuril
- Spandiuril
- Trifluoromethylhydrothiazide
- Vergonil
Hydroflumethiazide is a diuretic drug that is used to treat high blood pressure, heart failure, and edema. It decreases the production of aqueous humor by the eye, thereby decreasing intraocular pressure. Hydroflumethiazide also inhibits sodium reabsorption in the loop of Henle and helps to control hypertension. The drug increases renal excretion of water and electrolytes, which can lead to dehydration. Hydroflumethiazide has been shown to have an adverse effect on cardiovascular function due to its ability to inhibit ATP channels in cardiac cells and interfere with glomerular filtration rate (GFR). It has also been found to increase matrix metalloproteinases (MMP) activity in inflammatory bowel disease patients.
Propriedades químicas
Consulta técnica sobre: 3D-AAA13509 Hydroflumethiazide
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.